Solid Biosciences Past Earnings Performance
Past criteria checks 0/6
Solid Biosciences has been growing earnings at an average annual rate of 3.4%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 24% per year.
Key information
3.4%
Earnings growth rate
43.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 24.0% |
| Return on equity | -42.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Buy Solid Biosciences: Unpacking Its Main Value Driver
Apr 10Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
Jan 17Solid Biosciences to acquire gene therapy company AavantiBio
Sep 30Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results
Apr 30
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates
Apr 28We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Mar 17Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans
Oct 28We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Jul 13We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely
Mar 17Soild Bio sinks 13% after Sarepta data misses goal
Jan 08Solid Biosciences launches $90M private placement
Dec 11Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data
Nov 10Revenue & Expenses Breakdown
How Solid Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -90 | 28 | -6 |
| 31 Dec 23 | 0 | -96 | 28 | 0 |
| 30 Sep 23 | 0 | -91 | 24 | 78 |
| 30 Jun 23 | 0 | -90 | 24 | 78 |
| 31 Mar 23 | 6 | -91 | 24 | 25 |
| 31 Dec 22 | 8 | -86 | 24 | 0 |
| 30 Sep 22 | 11 | -89 | 29 | 59 |
| 30 Jun 22 | 15 | -87 | 29 | 59 |
| 31 Mar 22 | 12 | -81 | 28 | 59 |
| 31 Dec 21 | 14 | -72 | 27 | 0 |
| 30 Sep 21 | 10 | -75 | 26 | 65 |
| 30 Jun 21 | 7 | -78 | 24 | 65 |
| 31 Mar 21 | 3 | -78 | 22 | 65 |
| 31 Dec 20 | 0 | -88 | 22 | 65 |
| 30 Sep 20 | 0 | -99 | 21 | 27 |
| 30 Jun 20 | 0 | -107 | 23 | 50 |
| 31 Mar 20 | 0 | -114 | 23 | 71 |
| 31 Dec 19 | 0 | -117 | 25 | 95 |
| 30 Sep 19 | 0 | -107 | 24 | 85 |
| 30 Jun 19 | 0 | -97 | 21 | 77 |
| 31 Mar 19 | 0 | -89 | 21 | 69 |
| 31 Dec 18 | 0 | -75 | 18 | 58 |
| 30 Sep 18 | 0 | -67 | 16 | 52 |
| 30 Jun 18 | 0 | -62 | 15 | 48 |
| 31 Mar 18 | 0 | -55 | 14 | 43 |
| 31 Dec 17 | 0 | -39 | 15 | 40 |
| 30 Sep 17 | 0 | -29 | 13 | 35 |
| 31 Dec 16 | 0 | -17 | 5 | 20 |
Quality Earnings: SLDB is currently unprofitable.
Growing Profit Margin: SLDB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SLDB is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare SLDB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLDB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: SLDB has a negative Return on Equity (-42.83%), as it is currently unprofitable.